The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,¹ have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium-177-Dotatate (177-Lu-Dotatate; Lutathera) led to markedly longer progression-free survival and significantly higher response rates vs the control arm. {read more here}